Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18154903 | 0.85 | KMT2A (0.39) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL21874034 | 0.80 | KMT2A (0.37) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL6650809 | 0.78 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL8907523 | 0.77 | DDB1 (0.46) | KMT2A | |
| SCHEMBL71530 | 0.77 | DDB1 (0.46) | KMT2A | |
| SCHEMBL15058849 | 0.76 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30851322 | 0.76 | FABP5 (0.43) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL44676 | 0.73 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7767154 | 0.72 | FABP5 (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29598813 | 0.72 | FABP5 (0.54) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099937-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-12 | — | — | US | disclosed |
| EP-3283480-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166186-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099937-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | SMYD2, SETD2, SMYD3 | KMT2A 31/4885FABP5 3856/4885FABP7 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.